Business.com
Home » Directory » Pharmaceuticals & Biotechnology » Novartis Ag » Profile

Novartis Ag - NOVN- Profile


Website: http://www.novartis.com

Phone: +41 61 324 1111
Address:
CH-4002 Basel
4002 Basel,

Company Description
Novartis AG. The Group's principal activity is the development and manufacture of pharmaceuticals and nutritional products. The Group operates through four divisions; Pharmaceuticals, Consumer Health, Sandoz & Vaccines & Diagnostics. Pharmaceuticals Division includes drugs for use in transplantations, central nervous system disorders, cardiovascular, endocrine and respiratory diseases, dermatology, oncology, hematology and rheumatism and bone and hormone replacement therapy. Consumer Health Division includes Generics/OTC and sells copies of prescription medicines no longer under patent protection; medical nutrition and self-medication. Sandoz Division: Manufactures, distributes and sells generic pharmaceutical products and substances no longer subject to patent protection. Vaccines & Diagnostics Division provides innovative vaccines and a range of conventional products to combat viral and bacterial diseases. In 2006, the Group acquired Chiron Corporation & NeuTec Pharma plc. Pharmaceuticals accounted for 63% of 2006 revenues, Consumer Health, 18%, Sandoz, 17% & Vaccines & Diagnostics, 2%
Key People
Chairman, President & Chief Executive Dr. Daniel Vasella
Chief Financial Officer Raymund Breu
Vice Chairman Prof. Ulrich Lehner
Vice Chairman Hans-Joerg Rudloff
Secretary Monika Matti

Listings
Novartis AG
Discovers, develops, manufactures and markets arthritis, inflammation, bone, cardiovascular, metabolic, dermatology, hematology, neuroscience, and oncology drugs.
www.novartis.com
Breaking News
Forbes.com - 3 hours ago
ZURICH (Thomson Financial) - Swiss shares moved slightly higher in afternoon trade as Wall Street futures pointed to tentative gains in opening deals with Zurich Financial taking the lead after posting a solid set of first quarter results. At 1:20 p.m., ...
Forbes.com - 11 hours ago
ZURICH (Thomson Financial) - Novartis AG said new clinical data shows that Tekturna HCT, which is a single tablet combination of the direct renin inhibitor Tekturna and the diuretic hydrochlorothiazide (HCT) -- is twice as effective at reducing blood ...
ABC News - 11 hours ago
The global market for cancer drugs will grow twice as fast as that for all other pharmaceuticals as the developing world spends more on health care, a new report says. China, Brazil, Russia and other emerging countries are becoming bigger customers for ...
CNBC - 12 hours ago
WASHINGTON - The global market for cancer drugs will grow twice as fast as that for all other pharmaceuticals as the developing world spends more on health care, a new report says. China, Brazil, Russia and other emerging countries are becoming bigger ...
Reuters - 12 hours ago
(Reuters) - Novartis AG's (NOVN.VX: Quote, Profile, Research) blood pressure drug Tekturna is twice as effective at reducing high blood pressure than diuretic HCT alone, the company said on Thursday citing clinical data. Data presented at the American ...
Pharmaceutical Companies
Daily Drug Pipeline Updates Pharmaceutical Company Profiles
www.BioPharmInsight.com
Pfizer Prescription Help
Annual income under $34k to qualify Pfizer Connection to Care Program
www.myrxadvocate.com

Overview  |  Profile

B2B search marketing Free B2B search marketing whitepaper, 2008 B2B Search Marketing Strategy Guide: Advice From the Pros.
To advertise on Business.com, click here

Subscribe to

Try our free weekly WhatWorks
newsletter, with business how-to advice
& resources from Work.com.

click here to view a sample issue

Advertising Center | Advertiser Login | Featured Listings | Technology | News
© 2008 Business.com, Inc. All Rights Reserved. Privacy | Terms Of Use | Help | About Us | Jobs | Work.com
Other business products and services to help grow and manage your business